Emerging patterns in HIV integrase resistance
We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022-2024) in Portugal. Major resistance mutations were found in 5.5%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.
Authors
- Perpétua Gómes (ORCID: https://orcid.org/0000-0003-3271-8255)
- Joaquim Cabanas
- Inês Costa (ORCID: https://orcid.org/0000-0001-6026-3396)
- Fátima Gonçalves
- Victor Pimentel (ORCID: https://orcid.org/0000-0001-6390-4128)
- Margarida Veloso
- Isabel Diogo
- Ana Abecasis (ORCID: https://orcid.org/0000-0002-3903-5265)
- Marta Ribeiro (ORCID: https://orcid.org/0000-0001-7172-6173)
- Marta Pingarilho (ORCID: https://orcid.org/0000-0002-7928-3087)
- Sandra Bianchini Fernandes (ORCID: https://orcid.org/0000-0003-4325-6527)
Institutions
- Escola Superior de Saúde Egas Moniz (PT)
- Centro Hospitalar de Lisboa Ocidental (PT)
Publication Details
- Journal
- AIDS
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1097/qad.0000000000004322
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00